###begin article-title 0
###xml 43 49 <span type="species:ncbi:9606">Humans</span>
Prediction of Graft-Versus-Host Disease in Humans by Donor Gene-Expression Profiling
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
Graft-versus-host disease (GVHD) results from recognition of host antigens by donor T cells following allogeneic hematopoietic cell transplantation (AHCT). Notably, histoincompatibility between donor and recipient is necessary but not sufficient to elicit GVHD. Therefore, we tested the hypothesis that some donors may be "stronger alloresponders" than others, and consequently more likely to elicit GVHD.
###end p 2
###begin title 3
Methods and Findings
###end title 3
###begin p 4
###xml 60 61 60 61 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 69 70 69 70 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
To this end, we measured the gene-expression profiles of CD4+ and CD8+ T cells from 50 AHCT donors with microarrays. We report that pre-AHCT gene-expression profiling segregates donors whose recipient suffered from GVHD or not. Using quantitative PCR, established statistical tests, and analysis of multiple independent training-test datasets, we found that for chronic GVHD the "dangerous donor" trait (occurrence of GVHD in the recipient) is under polygenic control and is shaped by the activity of genes that regulate transforming growth factor-beta signaling and cell proliferation.
###end p 4
###begin title 5
Conclusions
###end title 5
###begin p 6
These findings strongly suggest that the donor gene-expression profile has a dominant influence on the occurrence of GVHD in the recipient. The ability to discriminate strong and weak alloresponders using gene-expression profiling could pave the way to personalized transplantation medicine.
###end p 6
###begin p 7
The donor gene expression profile appears to have a dominant influence on the occurrence of graft-versus-host disease in the recipient.
###end p 7
###begin title 8
Editors' Summary
###end title 8
###begin title 9
Background.
###end title 9
###begin p 10
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 1386 1392 <span type="species:ncbi:9606">people</span>
Human blood contains red blood cells, white blood cells, and platelets, which carry oxygen throughout the body, fight infections, and help blood clot, respectively. Normally, blood-forming (hematopoietic) stem cells in the bone marrow (and their offspring, peripheral blood stem cells) continually provide new blood cells. Tumors that arise from the bone marrow (such as leukemia and lymphoma, two types of hematopoietic tumor) are often treated by a bone marrow or peripheral blood stem cell transplant from a healthy donor to provide new blood-forming stem cells, as a follow-up to chemotherapy or radiotherapy designed to eradicate as much of the tumor as possible. This procedure is called allogeneic hematopoietic cell transplantation (AHCT)-the word allogeneic indicates that the donor and recipient are not genetically identical. When solid organs (for example, kidneys) are transplanted, the recipient's immune system can recognize alloantigens (proteins that vary between individuals) on the donor organ as foreign and reject it. To reduce the risk of rejection, the donor and recipient must have identical major histocompatibility complex (MHC) proteins. MHC matching is also important in AHCT but for further reasons. Here, donor T lymphocytes (a type of white blood cell) can attack the skin and other tissues of the host. This graft versus host disease (GVHD) affects many people undergoing AHCT despite MHC matching either soon after transplantation (acute GVHD) or months later (chronic GVHD). As an aside, the transplant may also act against the tumor itself-this is known as a graft versus leukemia effect.
###end p 10
###begin title 11
Why Was This Study Done?
###end title 11
###begin p 12
GVHD can usually be treated with drugs that damp down the immune system (immunosuppressive drugs), but it would be preferable to avoid GVHD altogether. Indeed, GVHD continues to be the leading cause of nonrelapse mortality following AHCT. Unfortunately, what determines who will develop GVHD after MHC-matched AHCT is unclear. Although GVHD only develops if there are some mismatches in histocompatibility antigens between the donor and host, it does not inevitably develop. Until now, scientists have mainly investigated whether differences between ACHT recipients might explain this observation. But, in this study, the researchers have examined the donors instead to see whether differences in their immune responses might make some donors stronger "alloresponders" than others and consequently more likely to cause GVHD.
###end p 12
###begin title 13
What Did the Researchers Do and Find?
###end title 13
###begin p 14
###xml 362 363 362 363 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 424 425 424 425 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 535 536 535 536 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 545 546 545 546 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
The researchers used a molecular biology technique called microarray expression profiling to examine gene expression patterns in the T lymphocytes of peripheral blood stem cell donors. From these patterns, they identified numerous genes whose expression levels discriminated between donors whose MHC-identical transplant recipient developed GVHD after AHCT (GVHD+ donors) and those whose recipient did not develop GVHD (GVHD- donors). The researchers confirmed that the expression levels of 17 of these genes discriminated between GVHD+ and GVHD- donors using a second technique called quantitative reverse transcriptase polymerase chain reaction. Many of these genes are involved in TGF-beta signaling (TGF-beta is a protein that helps to control the immune system), cell growth, or proliferation. The researchers also identified four gene pairs that interacted with each other to determine the likelihood that a given donor would induce GVHD. Finally, the researchers computationally retested their data and showed that the measurement of expression levels of each of these genes and of the four interacting gene pairs could correctly identify a donor sample likely to cause GVHD in up to 80% of samples.
###end p 14
###begin title 15
What Do These Findings Mean?
###end title 15
###begin p 16
###xml 972 980 <span type="species:ncbi:9606">patients</span>
These findings provide the first evidence that the donor's gene expression profile influences the development of GVHD in the recipient after AHCT. The researchers suggest that a "dangerous donor" (strong alloresponder) is a key factor in determining whether GVHD occurs after AHCT and propose that gene expression profiling of donor T lymphocytes might identify those donors likely to cause GVHD. Before this approach can be used to reduce the incidence of GVHD after AHCT, these findings need to be confirmed in many more donors. Also, the development of a test that is accurate enough for clinical use-one that does not miss dangerous donors but does not discard too many safe donors-may require the identification of larger groups of interacting genes. But, if it survives further investigation, the concept of a dangerous donor could represent an important advance in transplantation medicine, one that could help clinicians select low-risk donors for AHCT and tailor patients' immunosuppressive drug regimens according to their donor-determined risk of GVHD.
###end p 16
###begin title 17
Additional Information.
###end title 17
###begin p 18
Please access these Web sites via the online version of this summary at .
###end p 18
###begin p 19
###xml 32 40 <span type="species:ncbi:9606">patients</span>
* The  provides information for patients and physicians on all aspects of hematopoietic stem cell transplantation, including GVHD
###end p 19
###begin p 20
* The MedlinePlus encyclopedia has pages on ,  and
###end p 20
###begin p 21
* The US National Cancer Institute has a factsheet on
###end p 21
###begin title 22
Introduction
###end title 22
###begin p 23
###xml 94 95 94 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b001">1</xref>
###xml 96 97 96 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b003">3</xref>
###xml 433 434 433 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b004">4</xref>
###xml 435 436 435 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b005">5</xref>
###xml 778 779 778 779 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b006">6</xref>
###xml 780 781 780 781 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b007">7</xref>
###xml 893 894 893 894 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b008">8</xref>
###xml 895 896 895 896 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b009">9</xref>
###xml 1241 1243 1241 1243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b010">10</xref>
###xml 1287 1289 1287 1289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b011">11</xref>
###xml 1290 1292 1290 1292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b012">12</xref>
###xml 1631 1633 1631 1633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b012">12</xref>
###xml 361 365 <span type="species:ncbi:10090">mice</span>
###xml 736 741 <span type="species:ncbi:10090">mouse</span>
###xml 746 751 <span type="species:ncbi:9606">human</span>
###xml 792 797 <span type="species:ncbi:10090">mouse</span>
Graft-versus-host disease (GVHD) is initiated by donor T cell responses to host alloantigens [1-3]. However, the occurrence and severity of GVHD are not determined solely by the level of histoincompatibility between donor and recipient. Thus, two major histocompatibility complex (MHC)-identical individuals (excluding identical twins) or two inbred strains of mice will display over 50 minor histocompatibility antigen differences [4,5]. If histoincompatibility was sufficient for triggering GVHD, the rate of GVHD in MHC-matched recipients of allogeneic hematopoietic cell transplantation (AHCT) that receive no immunosuppressive agents should therefore be 100%. Under these conditions, however, GVHD was found in only 50% and 73% of mouse and human recipients, respectively [6,7]. Even in mouse MHC-mismatched AHCT models, some, but not all, donor strains induce severe acute GVHD (aGVHD) [8,9]. Thus, histoincompatibility is necessary, but not sufficient, to elicit fatal GVHD. Recent evidence suggests that aside from the mere presence of genetic polymorphisms, two host factors may influence the severity of aGVHD and chronic GVHD (cGVHD): elusive properties (for example, tissue distribution) of the immunodominant host alloantigens [10] and polymorphisms of host cytokine genes [11,12]. Another nonexclusive and largely unexplored rationale would be that some donors are "stronger alloresponders" than others because of quantitative or qualitative differences in immune responses. Indirect evidence for the latter hypothesis are reports suggesting that several donor genetic polymorphisms may correlate with GVHD severity [12].
###end p 23
###begin p 24
###xml 145 147 145 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b013">13</xref>
###xml 148 150 148 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b014">14</xref>
###xml 345 347 345 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b015">15</xref>
###xml 348 350 348 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b016">16</xref>
###xml 524 526 524 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b017">17</xref>
###xml 527 529 527 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b020">20</xref>
The seminal studies of Biozzi and colleagues have shown that the strength of B cell responses to natural immunogens is under multigenic control [13,14]. Approximately ten independently segregating loci endowed with additive effects are responsible for the major (240-fold) multispecific differences separating high- and low-antibody responders [15,16]. No similar data are available for T cell responses in general, and those against histocompatibility antigens in particular. Since GVHD is by far the main barrier in AHCT [17-20], identification of high-risk donors would allow better donor selection and tailoring of immunosuppressive regimens to GVHD risk. In addition to complex genetic trait linkages, it may also be assumed that environmental factors and donor immune system histories may contribute toward determining GVHD. While the latter two factors would be hidden from the analysis of inherited genetic traits or gene-sequence variation, they might be reflected in gene-expression signatures. We therefore chose to measure the activity of a broad range of genes with expression microarrays as a means of surveying the overall molecular-state signature of the donor immune system, independent of whether that state is largely determined by inherited genetic factors, environment, donor history, or mixtures thereof. The objective of our study was, therefore, to determine whether gene-expression profiling could discriminate AHCT donors that induced either aGVHD or cGVHD in their recipient host from donors who did not. In other words, is it possible to distinguish high from low alloresponders? Notwithstanding the fundamental importance of that question, a positive answer could pave the way to personalized transplantation medicine.
###end p 24
###begin title 25
Methods
###end title 25
###begin title 26
###xml 6 14 <span type="species:ncbi:9606">Patients</span>
Study Patients
###end title 26
###begin p 27
###xml 145 152 145 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040023-t001">Table 1</xref>
###xml 506 508 506 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b021">21</xref>
###xml 759 761 759 761 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b022">22</xref>
###xml 762 764 762 764 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b024">24</xref>
###xml 1106 1108 1106 1108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b019">19</xref>
###xml 5 13 <span type="species:ncbi:9606">patients</span>
###xml 325 333 <span type="species:ncbi:9606">patients</span>
###xml 767 775 <span type="species:ncbi:9606">Patients</span>
###xml 915 923 <span type="species:ncbi:9606">patients</span>
###xml 966 978 <span type="species:ncbi:9606">participants</span>
###xml 1018 1026 <span type="species:ncbi:9606">patients</span>
###xml 1050 1062 <span type="species:ncbi:9606">participants</span>
###xml 1151 1156 <span type="species:ncbi:9606">Human</span>
###xml 1280 1288 <span type="species:ncbi:9606">patients</span>
Only patients with hematological malignancies and their healthy sibling donors who were identical with regard to HLA participated in this study (Table 1). The AHCT myeloablative regimen consisted of cyclophosphamide (120 mg/kg) and total body irradiation (12 Gy), or busulfan (16 mg/kg) and cyclophosphamide (200 mg/kg). All patients received unmanipulated peripheral blood-stem-cell grafts (mobilized with G-CSF) and were given GVHD prophylaxis consisting of cyclosporine A and short-course methotrexate [21]. Donor blood samples were obtained one day prior to mobilization of peripheral blood-progenitor cells with G-CSF. Diagnosis of aGVHD and cGVHD was made after clinical evaluation and histologic confirmation according to previously reported criteria [22-24]. Patients with grade 0 and grades I-IV aGVHD were considered aGVHD- and +, respectively. Biopsies of skin and gut were carried out in 90% and 15% of patients with aGVHD, respectively; overall, 95% of participants with aGVHD had biopsies, including all patients with grade I GVHD. All participants with cGVHD showed extensive clinical GVHD [19]. Clinical protocols were approved by the Human Subjects Protection Committee of the Maisonneuve-Rosemont Hospital. Samples were obtained with the informed consent of the patients.
###end p 27
###begin p 28
Donor-Recipient Characteristics
###end p 28
###begin title 29
RNA Isolation, Amplification, and Microarray Hybridization
###end title 29
###begin p 30
###xml 3 4 3 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 12 13 12 13 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 499 500 498 499 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 507 508 506 507 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 306 311 <span type="species:ncbi:9606">human</span>
CD4+ and CD8+ T cells were enriched from peripheral blood mononuclear cells by positive isolation using magnetic microbeads (Dynal, ). Sample RNA was extracted using an RNA extraction kit (Qiagen, ), then amplified using the MessageAmp RNA kit (Ambion, ), as per the manufacturers' instructions. Universal human RNA (Stratagene, ) was amplified in the same way. Probes for microarray hybridization were prepared by labeling 3 mug of amplified RNA with Cy-3 (universal RNA; green values) or Cy-5 (CD4+ or CD8+ T cells; red values) by reverse transcription. Detailed information on the microarrays as well as the labeling and hybridization procedures can be obtained at The Microarray Centre of The Toronto University Health Network ().
###end p 30
###begin title 31
Microarray Data Preprocessing
###end title 31
###begin p 32
###xml 479 481 478 480 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">16</sup>
###xml 1100 1102 1099 1101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b025">25</xref>
###xml 1389 1390 1388 1389 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1399 1401 1398 1400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b026">26</xref>
###xml 2079 2081 2078 2080 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">10</sub>
Microarrays were scanned at 16 bits using the ScanArray Express scanner (Packard Bioscience, ) at 10-mum resolution at 635 (red)- and 532 (green)-nm wavelengths for Cy-5 and Cy-3, respectively, to produce image (tiff) files that were quantified using Genepix Pro 6.0 image-analysis software (Molecular Devices Corporation, ). Bad spots were flagged manually according to their morphologies. The results were saved as Quantarray files where the intensity values ranged from 0 to 216 - 1 (65,535) units. The tiff and Quantarray files were compressed and archived for permanent storage and further analysis. The microarrays were then screened for quality, first by visual inspection of the array with flagging of poor-quality spots, and second with automated scripts that scanned the quantified output files and measured overall density distribution on each channel and number of flagged spots. Box plots and density-distribution plots were drawn and inspected. Each quantified output file was run through the following preprocessing steps using the R language and environment () and the Limma package [25]. For minimum-intensity filtering, red and green values were treated with a surrogate-value replacement policy for estimating subthreshold values. For normalization within arrays, the raw merged red and green channels were lowess-normalized (grouped by print tip) and transformed to log2 ratios [26]. The commensurability of average brightness between the arrays of a pool of arrays was then assured using zero-centering of log-distributions normalization. For the ImmunArray design (The Microarray Centre of The Toronto University Health Network), each clone (gene) is represented by two independent spots, to provide for internal replicates. When both duplicate spots of a clone (gene) passed quality control, the average value of the duplicate clones was calculated and used as the representative value for that gene. If only one of the clone duplicate spots passed quality control, only that value was used in the downstream analysis. All data were then represented as log10 (red/green) expression ratios for further analysis.
###end p 32
###begin title 33
Quantitative Real-Time-PCR
###end title 33
###begin p 34
###xml 576 624 568 616 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">glyceraldehyde-3-phosphate dehydrogenase (GAPDH)</italic>
###xml 1473 1480 1435 1442 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(GAPDH)</italic>
###xml 1494 1500 1452 1458 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">target</sub>
###xml 1494 1500 1452 1458 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>target</sub></italic>
###xml 1505 1510 1463 1468 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</sub>
###xml 1505 1510 1463 1468 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>GAPDH</sub></italic>
###xml 1588 1594 1534 1540 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sample</sub>
###xml 1604 1614 1546 1556 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">calibrator</sub>
###xml 1756 1769 1698 1703 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;&#916;&#916;CT</sup>
###xml 347 352 <span type="species:ncbi:9606">human</span>
###xml 570 575 <span type="species:ncbi:9606">human</span>
###xml 1544 1549 <span type="species:ncbi:9606">human</span>
Total RNA was reverse transcribed in a final volume of 50 mul using the High Capacity cDNA Archive kit with random primers (Applied Biosystems, ) as described by the manufacturer. Reverse-transcribed samples were quantified using spectrophotometer measurements, diluted to a concentration of 5 ng/mul, and stored at -20 degreesC. A reference RNA (human reference total RNA [Stratagene]) was also transcribed to cDNA and was used as the calibrator. Gene-expression levels were determined using primer and probe sets from Applied Biosystems (ABI Assays on Demand []). The human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) predeveloped TaqMan assay (PN4326317E) was used as the endogenous control. PCR reactions were performed using 4 mul of cDNA samples (20 ng), 5 mul of the TaqMan Universal PCR Master mix (Applied Biosystems), and 0.5 mul of the TaqMan Gene Expression assays (20x) in a total volume of 10 mul. The ABI PRISM 7900HT Sequence Detection system (Applied Biosystems) was used to detect the amplification level, and was programmed to an initial step of 10 min at 95 degreesC, followed by 40 cycles of 15 s at 95 degreesC, and 1 min at 60 degreesC. All reactions were run in triplicate, and the average values of the triplicates were used for quantification. The relative expression level of target genes was determined by using the DeltaDeltaCT method. Briefly, the CT (threshold cycle) values of target genes were normalized to an endogenous control gene (GAPDH) (DeltaCT = CTtarget - CTGAPDH) and compared with a calibrator (human reference RNA): DeltaDeltaCT = DeltaCTsample - DeltaCTcalibrator. Relative expression (RQ) was calculated using the Sequence Detection system (SDS) 2.2.2 software (Applied Biosystems) and the formula RQ = 2-DeltaDeltaCT.
###end p 34
###begin title 35
Student's t-Test and Linear Discriminant Analysis
###end title 35
###begin p 36
###xml 410 411 410 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 740 742 740 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b027">27</xref>
###xml 1254 1256 1254 1256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b028">28</xref>
###xml 1568 1570 1568 1570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b029">29</xref>
###xml 1571 1573 1571 1573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b030">30</xref>
###xml 1843 1845 1843 1845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b028">28</xref>
The well-established univariate Student's t-test can determine whether the differences in expression for each gene are statistically significantly different in the aGVHD+ versus the aGVHD- and the cGVHD+ versus the cGVHD- sample classes, respectively. Specifically, given knowledge of the GVHD+ and GVHD- class arithmetic means and standard deviations from measurements, the t-test provides the probability or p-value of rejecting the null hypothesis of equal class means, given the null hypothesis being true (i.e., that both sample classes are essentially indistinguishable and derive from the same underlying distribution). It is also well established in practice that the t-test is robust against substantial departures from normality [27]. However, the t-test does not address per se the question of the robustness of class-prediction accuracy for a predictive model. A clinical user of such a model would ultimately like to predict whether a donor sample falls in the GVHD+ or GVHD- class, and what the expected accuracy and robustness of such a prediction would be. To this end, we used linear discriminant analysis (LDA) to estimate the accuracy of GVHD predictive genes discovered in microarray and quantitative real-time (qRT)-PCR experiments [28]. In addition, we assessed the robustness for all the genes validated by qRT-PCR by performing 500 independent instances of training-test dataset splits cross-validation to determine empirically through computational resampling the expected generalizable class-prediction accuracy on independent test datasets [29,30]. In LDA with assumed equal class a priori probabilities, the boundary between class P (GVHD+) and class N (GVHD-) is determined by the value of the separatrix, S, which is the point (in univariate analysis) between the class P and N means that is equidistant to both [28]. If the observed mean of class P is smaller than the observed mean of class N, all values less than or equal to S will be classified by the model as P, and all values greater than S will be classified as N. When the observed mean of class P is greater than the observed mean of class N, all values greater or equal to S will be classified by the model as P, and all values smaller than S will be classified as N. For all the samples that were classified by the model as P, the ones that also correspond to known P samples in the measured data constitute true positives, and the ones that correspond to known N samples in the measured data constitute false positives. For all the samples that were classified by the model as N, the ones that also correspond to known N samples in the measured data constitute true negatives, and the ones that correspond to known P samples in the measured data constitute false negatives. Accuracy rate is (true positives + true negatives)/total number of samples. Sensitivity is true positives/(true positives + false negatives), and specificity denotes true negatives/(true negatives + false positives).
###end p 36
###begin title 37
Predictive Interaction Analysis
###end title 37
###begin p 38
Predictive interaction analysis (PIA) was carried out on the 105 gene pairs formed by 15 genes that were individually predictive of GVHD in both microarray and qRT-PCR experiments. Gene pairs and single genes were compared as to their ability to distinguish GVHD+ from GVHD- samples according to the statistical methods outlined below.
###end p 38
###begin title 39
Two-class discriminant analysis.
###end title 39
###begin p 40
###xml 27 29 27 29 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b028">28</xref>
###xml 182 184 182 184 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">10</sub>
###xml 291 292 291 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</italic>
###xml 325 326 325 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</italic>
###xml 371 372 371 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</italic>
###xml 470 472 470 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b028">28</xref>
###xml 545 547 541 543 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 733 734 725 726 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sub>
###xml 732 734 724 726 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P<sub>c</sub></italic>
###xml 734 735 726 727 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 741 742 733 734 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sub>
###xml 740 742 732 734 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P<sub>c</sub></italic>
###xml 742 743 734 735 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 800 801 792 793 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sub>
###xml 796 801 788 793 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ln(P<sub>c</sub></italic>
###xml 801 802 793 794 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 804 805 796 797 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sub>
###xml 802 805 794 797 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">/P<sub>c</sub></italic>
###xml 805 806 797 798 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 806 807 798 799 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">)</italic>
###xml 851 852 843 844 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sub>
###xml 850 852 842 844 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P<sub>c</sub></italic>
###xml 852 853 844 845 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 857 858 849 850 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sub>
###xml 856 858 848 850 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P<sub>c</sub></italic>
###xml 858 859 850 851 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 1124 1125 1116 1117 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">.</italic>
Standard equations of LDA [28] are employed for determining two-class separations (GVHD+ versus GVHD-), based on single-gene or two-gene abundances. Column vector  represents the log10 abundances of a gene pair (mapping of gene pair abundances to a single variable is defined in PIA below). T denotes transpose. The variable c1 denotes one known class (e.g., GVHD+), and c2 denotes a second known class (e.g., GVHD-). The general two-class linear discriminant equation [28] is: where gene pair vectors  and  are the respective class means; Sigma-1 is the inverse of the gene pair by gene-pair data-derived pooled covariance matrix Sigma, which is the sample number-weighted sum of the data-derived within-class covariance matrices. Pc1 and Pc2 are the prior probabilities of the two classes. The ln(Pc2/Pc1) term in Equation 1 is zero because we set Pc2 = Pc1. In the LDA we are performing, the proportion of c2 samples compared to c1 samples in the data is not germane. Of relevance in the LDA are the individual sample data values, the class means, and the within-class variations, not the class prior probabilities per se. Setting Equation 1 to zero defines the general equation for the separatrix L: where parameter vector  and scalar  are data-dependent constants. The general L then can be written immediately in slope/intercept form as where  . However, in the PIA to be described below we use a specialized, deliberately constrained form of Equation 3. Namely, the separatrix L has slope -1 (synergistic PIA [SPIA]), or +1 (competitive PIA [CPIA]), and necessarily bisects the chord between the two class means  and  .
###end p 40
###begin title 41
CPIA and SPIA.
###end title 41
###begin p 42
###xml 12 13 12 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">X</italic>
###xml 16 17 16 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Y</italic>
###xml 27 28 27 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">X</italic>
###xml 38 39 38 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Y</italic>
###xml 136 139 136 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">X/Y</italic>
###xml 144 147 144 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Y/X</italic>
###xml 158 159 158 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">X</italic>
###xml 169 170 169 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Y</italic>
###xml 253 254 253 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">x</italic>
###xml 257 260 257 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">log</italic>
###xml 260 262 260 262 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">10</sub>
###xml 262 268 262 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(X), y</italic>
###xml 271 274 271 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">log</italic>
###xml 274 276 274 276 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">10</sub>
###xml 276 280 276 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(Y),</italic>
###xml 310 311 310 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">u</italic>
###xml 314 315 314 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">x</italic>
###xml 318 319 318 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">y</italic>
###xml 324 325 324 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</italic>
###xml 328 329 328 329 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">x</italic>
###xml 332 333 332 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">y</italic>
###xml 355 361 355 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(x, y)</italic>
###xml 389 390 389 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">u</italic>
###xml 455 456 455 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</italic>
###xml 583 589 583 589 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(x, y)</italic>
###xml 606 607 606 607 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">u</italic>
###xml 610 611 610 611 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">x</italic>
###xml 614 615 614 615 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">y</italic>
###xml 618 626 618 626 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">constant</italic>
###xml 642 643 642 643 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">y</italic>
###xml 647 648 647 648 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">x</italic>
###xml 651 660 651 660 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">constant,</italic>
###xml 750 756 750 756 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(x, y)</italic>
###xml 773 774 773 774 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</italic>
###xml 777 778 777 778 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">x</italic>
###xml 781 782 781 782 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">y</italic>
###xml 785 793 785 793 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">constant</italic>
###xml 809 810 809 810 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">y</italic>
###xml 813 814 813 814 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">x</italic>
###xml 817 825 817 825 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">constant</italic>
The product X x Y for gene X and gene Y represents a synergistic phenomenological gene-gene interaction (SPIA), and the abundance ratio X/Y (or Y/X) for gene X and gene Y represents a competitive phenomenological gene-gene interaction (CPIA). We define x = log10(X), y = log10(Y), and new coordinates or axes: u = x + y and v = x - y. Class separation in (x, y) with respect to univariate u is termed SPIA, and class separation with respect to univariate v is termed CPIA. PIA refers to either SPIA or CPIA. Hence, good class separation in SPIA is demonstrated by good separation in (x, y) by a separatrix u = x + y = constant (equivalent to y = -x + constant, i.e., slope -1), and good class separation in CPIA is demonstrated by good separation in (x, y) by a separatrix v = x - y = constant (equivalent to y = x - constant, i.e., slope +1). Thus, we apply LDA under models restricted to separatrices whose slopes are constrained deliberately to -1 or +1.
###end p 42
###begin title 43
Classification performance measures.
###end title 43
###begin p 44
###xml 79 80 79 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 276 281 276 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(X,Y)</italic>
###xml 337 345 337 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">x, y, u,</italic>
###xml 350 351 350 351 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</italic>
###xml 369 374 369 374 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(x,y)</italic>
###xml 412 413 412 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">x</italic>
###xml 466 467 466 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 598 599 598 599 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">y</italic>
###xml 602 603 602 603 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">u</italic>
###xml 610 611 610 611 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</italic>
###xml 793 794 793 794 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 816 817 816 817 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">u</italic>
###xml 824 825 824 825 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</italic>
###xml 834 835 834 835 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">x</italic>
###xml 843 844 843 844 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">y</italic>
###xml 871 876 871 876 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(X,Y)</italic>
###xml 915 916 915 916 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">u</italic>
###xml 925 926 925 926 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</italic>
###xml 976 977 976 977 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">x</italic>
###xml 1014 1015 1014 1015 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">y</italic>
We use straightforward sampling statistics to characterize class separation by p-values, as well as by counts of correctly classified samples relative to the total number of samples being classified (univariate LDA accuracies). The class-separation performance of a gene pair (X,Y) in SPIA or CPIA can be assessed readily on single axes x, y, u, and v. When samples in (x,y) are, for example, projected onto the x-axis, classification performance is assessed by the p-value returned by a simple homoscedastic t-test for differences of two means. This is computed analogously and separately for the y-, u-, and v-axes. It is important-because of the biological interpretations offered by SPIA and CPIA-to focus on those gene pairs for which two-class separation (as assessed by intercomparable p-values) is better in u or in v than in x and in y. Thus, we seek gene pairs (X,Y) for which along the "single variable" u-axis or v-axis, the classes separate better than along the x-axis only and better than along the y-axis only.
###end p 44
###begin title 45
Results
###end title 45
###begin title 46
Experimental Model
###end title 46
###begin p 47
###xml 459 467 459 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040023-g001">Figure 1</xref>
###xml 750 751 750 751 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 759 760 759 760 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 497 502 <span type="species:ncbi:9606">human</span>
###xml 1029 1034 <span type="species:ncbi:9606">human</span>
In our quest for a GVHD-predictive signature, our prime objective was to correlate global gene-expression profiling of AHCT donor T cells with the occurrence of GVHD in recipients. A secondary objective was to evaluate whether the donor gene-expression profile persisted long-term in the recipient. Peripheral blood was obtained from 50 AHCT donors pretransplant (referred to as day 0) and from 40 recipients on day 365 (ten recipients were dead by day 365) (Figure 1). Donors and recipients were human leukocyte antigen-identical siblings. Recipients were regarded as negative for aGVHD when they lived at least 100 days without presenting GVHD. Recipients were considered negative for cGVHD when they remained cGVHD-free for 365 days post-AHCT. CD4+ and CD8+ T cell subsets were purified with microbeads. Total RNA was purified, amplified, reverse transcribed, and hybridized on microarrays developed by The Microarray Centre of The Toronto University Health Network. RNA from donor and recipient T cells was hybridized on the human H19K array (19,008 expressed sequence tags), and donor T cell RNA was also hybridized on the ImmunArray (3,411 ESTs from immune-related genes). The ImmunArray provides additional genes for better coverage of immune responses to complement the H19K array.
###end p 47
###begin title 48
Study Design
###end title 48
###begin p 49
###xml 102 103 102 103 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 111 112 111 112 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 168 173 <span type="species:ncbi:9606">human</span>
Donor and recipient T cells were obtained on days 0 and 365, respectively. Total RNA from purified CD4+ and CD8+ T cells was reversed transcribed and hybridized on the human H19K array (donor and recipient T cells) and the ImmunArray (donor T cells) from The Microarray Centre of The Toronto University Health Network.
###end p 49
###begin p 50
###xml 137 139 137 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b031">31</xref>
###xml 140 142 140 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b034">34</xref>
###xml 573 575 573 575 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b035">35</xref>
###xml 628 629 628 629 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 637 638 637 638 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 721 723 721 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b036">36</xref>
###xml 754 755 754 755 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 763 764 763 764 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 804 806 804 806 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b037">37</xref>
###xml 819 820 819 820 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 828 829 828 829 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 927 929 927 929 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b038">38</xref>
###xml 930 932 930 932 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b039">39</xref>
The success rate of gene-expression profiling studies decreases with the degree of biological noise inherent to the experimental system [31-34]. Accordingly, our study design included four features to reduce biological noise. First, unlike recipients of solid organ grafts who inevitably present organ failure (e.g., renal insufficiency), AHCT donors are healthy individuals. This is important because serious ailments (and their treatment) cause alterations in global gene expression that are significantly greater than the background variation in normal gene expression [35]. Second, our studies were performed on purified CD4+ and CD8+ T cells because cell lineage is a primary determinant of gene-expression profile [36], and the transcriptome of CD4+ and CD8+ T cells shows significant differences [37]. Third, CD4+ and CD8+ T cells are necessary and sufficient for induction of antiminor histocompatibility antigen GVHD [38,39], the clinical endpoint of this study. Fourth, AHCT recipients were treated in a single center using standardized therapeutic regimens and uniform criteria for diagnosis of GVHD.
###end p 50
###begin title 51
Donor T Cell Gene-Expression Profiling Using Microarrays
###end title 51
###begin p 52
###xml 196 197 196 197 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 205 206 205 206 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 680 681 678 679 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 692 700 688 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040023-g002">Figure 2</xref>
###xml 774 776 770 772 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b019">19</xref>
###xml 850 858 846 854 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040023-g002">Figure 2</xref>
###xml 935 936 931 932 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 944 945 940 941 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 961 969 957 965 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040023-g002">Figure 2</xref>
###xml 1045 1046 1041 1042 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1053 1054 1049 1050 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1122 1130 1118 1126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040023-g002">Figure 2</xref>
###xml 1296 1304 1292 1300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040023-st001">Table S1</xref>
###xml 1365 1373 1361 1369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040023-st002">Table S2</xref>
###xml 1529 1530 1525 1526 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1556 1557 1552 1553 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
We first carried out eight searches for class-discriminating genes using two methods, a statistical t-test and a specially constrained LDA, over four class divisions. Class divisions were, for CD4+ and CD8+ T cells: (i) recipients with no GVHD versus those with aGVHD (with or without cGVHD); and (ii) recipients with no GVHD versus those with cGVHD (with or without aGVHD). Recipients were considered GVHD- only when they presented no signs of GVHD after a minimum follow-up of one year post-AHCT. We selected for analysis genes showing a GVHD-predictive LDA accuracy (ability to discriminate donors whose recipient presented GVHD or not) >/= 65% and class discrimination t-test p </= 0.05 (Figure 2A). Consistent with the notion that aGVHD strongly correlates with cGVHD [19], many of the genes predictive for aGVHD were also predictive for cGVHD (Figure 2B). A substantial proportion of GVHD-predictive genes were common to both CD4+ and CD8+ donor T cells (Figure 2C). However, the fact that most GVHD-associated genes were found in only CD4+ or CD8+ T cells supports the need to analyze T cell subsets independently (Figure 2C). Among genes emerging from the ImmunArray and H19K datasets, those that are annotated and have a demonstrated or putative function in T cell biology are listed in Table S1 (genes overexpressed in GVHD+ relative to GVHD- donors) and Table S2 (genes repressed in GVHD+ donors). Overall, the numbers of genes that were up-regulated/down-regulated in GVHD+ relative to GVHD- donors were 22/42 for CD4+ T cells and 31/40 for CD8+ T cells. About 60% of these genes are involved in cell proliferation, signal transduction, or transcription (unpublished data).
###end p 52
###begin title 53
GVHD Predictive Genes Identified by One-Dimensional Analyses
###end title 53
###begin p 54
Searches were performed using two methods: a linear discriminant-analysis-based approach and statistical t-test.
###end p 54
###begin p 55
###xml 67 68 65 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
(A) Number of genes showing a GVHD-predictive accuracy >/= 65% and p </= 0.05.
###end p 55
###begin p 56
###xml 141 142 141 142 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 153 154 153 154 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
(B and C) Data from the H19K and ImmuArray were pooled. Among GVHD-predictive genes, Venn diagrams represent counts relationships between CD4+ versus CD8+ T-cell gene profiles (B) and aGVHD versus cGVHD predictive-genes (C).
###end p 56
###begin title 57
qRT-PCR Analyses of GVHD-Predictive Genes
###end title 57
###begin title 58
Predictive value of single genes.
###end title 58
###begin p 59
###xml 151 152 151 152 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 154 155 154 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 169 170 169 170 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 172 173 172 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 288 296 288 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040023-st001">Table S1</xref>
###xml 301 309 301 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040023-st002">Table S2</xref>
###xml 719 727 719 727 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040023-st001">Table S1</xref>
###xml 732 740 732 740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040023-st002">Table S2</xref>
###xml 1014 1018 1005 1009 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGIF</italic>
###xml 1040 1047 1028 1035 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(TGFBI)</italic>
###xml 1280 1281 1265 1266 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
To evaluate the validity of predictive genes identified with microarrays, we performed qRT-PCR analyses on fresh mRNA aliquots extracted from donor CD4+ (n = 33) and CD8+ (n = 35) T cells. We focused on cGVHD-predictive genes and tested a total of 26 genes, including 24 genes present in Table S1 and Table S2. We selected the latter 24 genes based on two criteria: they are involved in cell proliferation and/or cytokine signaling and were differentially expressed in cGVHD+ versus cGVHD- donors. Analyzing several genes involved in a common signaling cascade has special interest because it provides a unique opportunity to validate the biological coherence of differentially expressed genes. Preliminary analysis of Table S1 and Table S2 showed that at least five cGVHD-predictive genes were components of the transforming growth factor-beta (TGF-beta) signaling pathway. These five genes were selected for quantitative PCR studies. To further evaluate the possible role of the TGF-beta pathway, we also tested TGIF and TGF-beta-induced (TGFBI) (which were not present on the microarrays), which are transcriptional targets of TGF-beta. Performance of individual genes was evaluated using univariate Student's t-test and LDA. The statistical significance corresponds to t-test p-value, whereas classification performance (sensitivity, specificity, and overall accuracy) was derived from LDA.
###end p 59
###begin p 60
###xml 60 67 60 67 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040023-t002">Table 2</xref>
###xml 239 241 239 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b034">34</xref>
###xml 332 339 332 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040023-t002">Table 2</xref>
###xml 365 373 365 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040023-st001">Table S1</xref>
###xml 378 386 378 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040023-st002">Table S2</xref>
###xml 548 549 545 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 730 731 727 728 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 741 742 738 739 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 924 928 921 925 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRF1</italic>
###xml 958 966 955 963 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040023-g003">Figure 3</xref>
###xml 968 975 965 972 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040023-t002">Table 2</xref>
###xml 978 982 975 979 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRF1</italic>
###xml 1031 1032 1028 1029 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1081 1087 1078 1084 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMAD3,</italic>
###xml 1189 1197 1183 1191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040023-g003">Figure 3</xref>
###xml 1199 1206 1193 1200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040023-t002">Table 2</xref>
###xml 1224 1229 1218 1223 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMAD3</italic>
###xml 1248 1249 1242 1243 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1372 1377 1366 1371 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMAD3</italic>
###xml 1741 1749 1735 1743 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040023-g003">Figure 3</xref>
###xml 1772 1777 1766 1771 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMAD3</italic>
###xml 1868 1873 1862 1867 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMAD3</italic>
###xml 1886 1894 1880 1888 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040023-g003">Figure 3</xref>
###xml 1948 1953 1942 1947 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMAD3</italic>
qRT-PCR did not confirm the predictive value of nine genes (Table 2). This result can be explained by the limited sample size and the idiosyncrasies of the two mRNA-measurement procedures (e.g., cross-hybridization and splicing variants) [34]. Out of the 26 genes tested, 17 were differentially expressed in GVHD+ and GVHD- donors (Table 2): 15 genes selected from Table S1 and Table S2 (they showed consistent change directionality in microarrays and qRT-PCR) plus the two supplementary TGF-beta target genes. The statistical significance (t-test p- value) of individual cGVHD-predictive genes ranged from 0.046 to 0.0005, and their GVHD-predictive accuracy (LDA) from 63% to 80%. Of note, there was a weak negative correlation (r = -0.53, p = 0.03) between the specificity and sensitivity of the 17 genes. Thus, some genes were better in predicting the occurrence of GVHD than its absence, and vice versa for other genes. PRF1 showed the best specificity (Figure 3; Table 2). PRF1 codes for perforin, whose high expression in CD8+ T cells was associated with occurrence of GVHD. SMAD3, a transcription factor that is activated following TGF-beta binding, showed the highest sensitivity (Figure 3; Table 2). High levels of SMAD3 transcripts in CD4+ T cells correlated with absence of GVHD. Based on the LDA-generated class separatrix, the specificity and sensitivity for SMAD3 were 53% and 89% with an overall accuracy of 73%. We repositioned post-hoc the separatrix in order to have all cGVHD+ donors on one side of the separatrix (hereafter referred to as the 100% cGVHD+ separatrix). This new separatrix, which by definition increased the sensitivity to 100%, also increased the overall accuracy to 79% without changing the specificity (Figure 3). Thus, low levels of SMAD3 were found in all GVHD+ and some GVHD- donors, while all donors expressing high levels of SMAD3 were GVHD- (Figure 3). Mechanistically, this suggests that high levels of SMAD3 are sufficient (but not necessary) to prevent GVHD, while low levels are necessary (but not sufficient) for the occurrence of GVHD.
###end p 60
###begin p 61
qRT-PCR Analyses of GVHD-Predictive Genes
###end p 61
###begin title 62
###xml 42 47 42 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMAD3</italic>
###xml 52 56 52 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRF1</italic>
LDA-Based Scatterplot of qRT-PCR Data for SMAD3 and PRF1
###end title 62
###begin p 63
###xml 14 19 14 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMAD3</italic>
###xml 28 32 28 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRF1</italic>
###xml 65 66 65 66 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 74 75 74 75 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 262 268 262 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMAD3,</italic>
Levels of (A) SMAD3 and (B) PRF1 transcripts were assessed in CD4+ and CD8+ T cells, respectively. Data for all donors tested by qRT-PCR were ranked according to relative gene expression levels. Thick horizontal black line corresponds to the LDA separatrix. For SMAD3, a computationally repositioned separatrix for 100% GVHD+ discrimination is shown (red line).
###end p 63
###begin p 64
###xml 172 174 172 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b036">36</xref>
###xml 175 177 175 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b040">40</xref>
###xml 360 367 357 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040023-t002">Table 2</xref>
###xml 435 469 432 466 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EP300, FURIN, FNBP3, SMAD3, TGFBI,</italic>
###xml 474 479 471 476 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGIF,</italic>
###xml 498 503 495 500 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRF1.</italic>
###xml 670 672 664 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b041">41</xref>
###xml 673 675 667 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b047">47</xref>
###xml 830 869 824 863 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(AKT2, ATBF1, CD24, CD151, MYCL1, NFAT5</italic>
###xml 871 889 865 883 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NMI, SIL, SH3KBP1,</italic>
###xml 894 900 888 894 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCIRG1</italic>
###xml 903 905 897 899 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b048">48</xref>
###xml 906 908 900 902 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b057">57</xref>
One major point highlighted by gene-expression profiling studies is the primacy of pathways over the effects of individual genes (pathways ultimately define the profiles) [36,40]. With this in mind, a most salient finding was that all components and targets of the TGF-beta pathway tested by qRT-PCR were differentially expressed in GVHD+ versus GVHD- donors (Table 2). Compared with GVHD+ donors, GVHD- donors showed up-regulation of EP300, FURIN, FNBP3, SMAD3, TGFBI, and TGIF, and repression of PRF1. From a pathway perspective, that expression profile is entirely consistent and points to increased TGF-beta signaling in T cells from GVHD- relative to GVHD+ donors [41-47]. The ten other cGVHD-predictive genes whose differential expression was confirmed by qRT-PCR are involved in regulation of cell growth and proliferation (AKT2, ATBF1, CD24, CD151, MYCL1, NFAT5, NMI, SIL, SH3KBP1, and TCIRG1) [48-57].
###end p 64
###begin title 65
PIAs using a pairwise interaction model.
###end title 65
###begin p 66
###xml 253 255 253 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b058">58</xref>
###xml 256 258 256 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b059">59</xref>
###xml 481 482 481 482 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">X</italic>
###xml 492 493 492 493 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Y</italic>
###xml 549 552 549 552 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Y/X</italic>
###xml 663 666 663 666 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Y/X</italic>
###xml 803 804 803 804 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">X</italic>
###xml 807 808 807 808 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Y</italic>
###xml 1076 1083 1076 1083 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040023-t002">Table 2</xref>
###xml 1141 1142 1141 1142 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1143 1144 1143 1144 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1229 1230 1229 1230 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1384 1392 1384 1392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040023-g004">Figure 4</xref>
###xml 1414 1420 1414 1420 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NFAT5,</italic>
###xml 1502 1504 1502 1504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b053">53</xref>
###xml 1541 1548 1541 1548 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SH3KBP1</italic>
###xml 1556 1561 1556 1561 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CIN85</italic>
###xml 1633 1635 1633 1635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b056">56</xref>
###xml 1647 1652 1647 1652 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRF1,</italic>
###xml 1686 1687 1686 1687 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1736 1738 1736 1738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b060">60</xref>
###xml 1769 1773 1769 1773 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRF1</italic>
###xml 1808 1814 1808 1814 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCIRG1</italic>
###xml 1822 1827 1822 1827 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TIRC7</italic>
###xml 1895 1897 1895 1897 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b057">57</xref>
###xml 1909 1915 1909 1915 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CD151,</italic>
###xml 1973 1975 1973 1975 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b051">51</xref>
###xml 2012 2016 2012 2016 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SIL,</italic>
###xml 2080 2082 2080 2082 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b061">61</xref>
A global approach is required to properly understand cellular responses, because interpathway cross-talk and other properties of networks reflect underlying complexities that cannot be explained by the consideration of individual pathways in isolation [58,59]. In their simplest form, gene-gene interactions may be phenomenologically competitive or synergistic. We posited that such interactions might be reflected in particular gene-pair expression patterns. For example, if gene X and gene Y represent a competitive interaction, the ratio of gene Y/X expression should determine GVHD outcome (e.g., presence and absence of GVHD will correlate with high and low Y/X ratios, respectively). Alternatively, for synergistic interactions, the occurrence of GVHD should be regulated by the product of genes' X x Y activities. We therefore examined gene-pair expression ratios and products within the context of competitive and synergistic models. To this end, we evaluated the gene pairs formed by the 15 GVHD-predictive genes validated in both microarray and qRT-PCR experiments (Table 2). The total number of gene pairs analyzed corresponds to n(n - 1)/2 (i.e., 105). We asked whether CPIA and SPIA would highlight gene pairs whose p-value for cGVHD versus no GVHD was at least 10-fold lower than that of constituent genes. A total of four gene pairs satisfied this stringent criterion (Figure 4A). PIAs suggest that NFAT5, a transcription factor that regulates gene expression induced by osmotic stress [53], has competitive interactions with SH3KBP1 (alias CIN85), which interacts with CBL (a negative regulator of immune signaling) [56], and with PRF1, a quintessential component of CD8+ T cell granule exocytosis cytotoxicity pathway [60]. Likewise, PIAs suggest that PRF1 has competitive interactions with TCIRG1 (alias TIRC7), a negative regulator of T cell activation and cytokine response [57]; and that CD151, a negative regulator of Ag-induced T cell proliferation [51], collaborates synergistically with SIL, a gene whose expression is associated with cell proliferation [61]. From a mechanistic perspective, these data suggest that interactions between the four pairs' constituent genes are biologically relevant and should be investigated.
###end p 66
###begin title 67
Competitive and Synergistic Interactions between GVHD-Predictive Genes
###end title 67
###begin p 68
###xml 41 42 41 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 176 182 176 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NFAT5,</italic>
###xml 187 195 187 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SH3KBP1,</italic>
###xml 208 221 208 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NFAT5/SH3KBP1</italic>
(A) PIA identified four gene pairs whose p-value for cGVHD prediction was at least 10-fold lower than that of constituent genes. LDA-based scatterplots of qRT-PCR data for (B) NFAT5, (C) SH3KBP1, and (D) the NFAT5/SH3KBP1 gene pair. Dotted lines represent LDA-generated separatrices. Red lines correspond to 100% cGVHD+ separatrices (designed to maximize sensitivity).
###end p 68
###begin p 69
###xml 182 195 182 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SH3KBP1/NFAT5</italic>
###xml 340 348 340 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040023-g004">Figure 4</xref>
###xml 496 504 496 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040023-g004">Figure 4</xref>
###xml 547 560 547 560 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SH3KBP1/NFAT5</italic>
###xml 911 912 911 912 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1164 1166 1164 1166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b030">30</xref>
###xml 1029 1041 <span type="species:ncbi:9606">participants</span>
Gene pairs discovered by PIA can provide better performance than constituent single genes in terms of prediction accuracy. Performance gain is illustrated by further analyses of the SH3KBP1/NFAT5 gene pair using LDA and two class-separatrices: the LDA-generated separatrix and the 100% cGVHD+ separatrix (designed to maximize sensitivity) (Figure 4). Compared to the LDA-generated separatrix, the 100% cGVHD+ separatrix increased the sensitivity by 22%-39% without compromising overall accuracy (Figure 4). Using the LDA-generated separatrix, the SH3KBP1/NFAT5 gene pair provided a 6% gain in both sensitivity and overall accuracy compared with single genes. With the 100% cGVHD+ separatrix (which by definition gives a 100% sensitivity), the overall accuracy gain was 8%. From a clinical standpoint, these data suggest that PIAs can identify gene pairs with greatly enhanced predictive accuracies and stronger p-values compared to their constituent genes. Furthermore, they imply that in further studies with a larger number of participants, higher-order combinatorial searches could significantly improve the prediction performance of gene-expression profiling [30].
###end p 69
###begin title 70
Multiple training-test dataset split cross-validation.
###end title 70
###begin p 71
###xml 83 84 83 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 531 532 531 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1285 1287 1285 1287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b030">30</xref>
###xml 1338 1340 1338 1340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b029">29</xref>
###xml 1397 1404 1397 1404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040023-t002">Table 2</xref>
###xml 1467 1475 1467 1475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040023-g004">Figure 4</xref>
###xml 1827 1828 1827 1828 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2007 2008 2007 2008 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
We can be confident that genes with good cGVHD+- and cGVHD--differentiating t-test p-values over the complete set of samples have a statistically significant ability to distinguish between these classes (in terms of rejecting the equal means null hypothesis). However, the assessment of LDA classification accuracy on a single set of samples may not be robust, since accuracy could be highly sensitive to chance fluctuations of measurement points in the vicinity of the separatrix. Such situations might not have a large impact on p-value, but can disproportionately affect accuracy assessments. To establish whether cGVHD+/- discrimination accuracy may be generalizable and robust, we need to determine the accuracy of the model prediction on test datasets that are independent (with regard to sampling) of the training datasets from which the predictive LDA models are derived. However, a single instance of training-test dataset comparison can be considered neither representative nor robust, since it is potentially sensitive to idiosyncratic fluctuations of datapoints around the separatrix. We therefore determined the robust average accuracy over many independently generated test datasets for each gene, on the basis of different selections of training-set data for each gene [30], using conventional cross-validation procedures [29]. These analyses were performed on the 17 single genes (Table 2) and the PIA variables representative of the four gene pairs (Figure 4A) that were predictive of cGVHD occurrence. Specifically, for each gene, we carried out 500 different 60% training samples and 40% test-samples dataset splits by randomly assigning (for each data split) 60% of the respective cGVHD+ and cGVHD- samples to a training dataset, and the remaining 40% of the samples to the respective test datasets. For CD4+ cells, 11 cGVHD+ and nine cGVHD- samples were selected randomly for training datasets, while the seven cGVHD+ and six cGVHD- remaining samples were used in test datasets. For CD8+ cells, 11 cGVHD+ and ten cGVHD- samples were selected randomly for training datasets, while the remaining seven cGVHD+ and seven cGVHD- samples were used in test datasets. The test dataset accuracy was determined separately for each of the 500 training/test random-sampling splits by using the LDA-predictive model separatrix from the corresponding training dataset. We emphasize that each test dataset-accuracy determination for each gene was carried out 500 separate times on randomly chosen dataset splits, each time using a predictive model that has never been exposed to the test data.
###end p 71
###begin p 72
###xml 210 218 210 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040023-g005">Figure 5</xref>
###xml 322 327 320 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CD151</italic>
###xml 335 336 333 334 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 383 387 379 383 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRF1</italic>
###xml 395 396 391 392 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 562 571 556 565 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CD151&#8211;SIL</italic>
###xml 631 636 623 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CD151</italic>
###xml 641 644 633 636 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SIL</italic>
###xml 726 734 714 722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040023-g005">Figure 5</xref>
We report for each gene the robust cross-validation ensemble average test-set accuracy and its standard deviation, as well as bar graphs depicting occurrences of specific accuracies in 10% accuracy increments (Figure 5). We found that the average test-set cross-validation accuracy was 71% +/- 10%, and that genes such as CD151 for CD4+ cells achieved an accuracy of 77% +/- 9%, and PRF1 for CD8+ cells achieved 76% +/- 10%. Notably, the test-set cross-validation accuracy of gene pairs identified by PIA often outperforms that of single genes. For example, the CD151-SIL gene pair achieved 80% +/- 9%, while its constituent genes CD151 and SIL provided accuracies of 77% +/- 9% and 69% +/- 10%, respectively. In addition, in Figure 5 we see a conspicuous shift of occurrences of accuracies from the 70% and 80% histogram bins for the constituent genes to the 90% and 100% bins for the gene pairs. These data provide strong evidence that the 17 genes and four gene pairs reported herein not only show statistically significant differences between cGVHD+ and cGVHD- donors, but also that these differences are substantial in magnitude and robustly provide higher than 70% accuracies overall. We therefore infer that the robust discrimination performance of these genes and gene pairs could be of clinical value for cGVHD prediction.
###end p 72
###begin title 73
Multiple Training-Test Dataset Split Cross-Validation
###end title 73
###begin p 74
###xml 22 23 22 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 52 53 52 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
For each single gene (n = 17, blue) and gene pairs (n = 4, red), we carried out 500 different 60% training samples and 40% test samples dataset splits by randomly assigning 60% of the respective cGVHD+ and cGVHD- samples to a training dataset and the remaining 40% of the samples to the respective test datasets. The test dataset accuracy was determined separately for each of the 500 training/test random sampling splits by using the LDA predictive model separatrix from the corresponding training dataset. Bar graphs show the occurrence of specific accuracies in 10% accuracy increments. Numbers in each panel represent the mean test-set accuracy (%) +/- standard deviation.
###end p 74
###begin title 75
The Microarray-Based Donor Gene Profile Persists Long-Term in the Recipient
###end title 75
###begin p 76
###xml 340 342 340 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b062">62</xref>
###xml 343 345 343 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b065">65</xref>
###xml 428 429 428 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 471 472 471 472 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 946 954 946 954 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040023-st003">Table S3</xref>
###xml 1190 1192 1190 1192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b036">36</xref>
###xml 1377 1378 1377 1378 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 1383 1384 1383 1384 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 1469 1470 1469 1470 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 1475 1476 1475 1476 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 1552 1553 1552 1553 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 1558 1559 1558 1559 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
To determine whether differences in donor gene-expression profiles were transferable, we evaluated whether they persisted in the recipient. All our recipients were adults that were given a myeloablative-conditioning regimen and received a non-T cell-depleted AHCT. In these conditions, essentially all T cells on day 365 are donor-derived [62-65]. We therefore studied the relationship between the donor gene profiles on day 0 (t0) and the recipient profiles on day 365 (t3). In other words, we compared the transcriptome of T cells derived from a single zygote (the donor) but residing in two types of environments (the donor and the recipient). To get a manageable yet broad basis for analyses, we included two gene sets tested on the H19K chip: the top 400 genes showing differential expression in GVHD+ versus GVHD- donors on day 0, combined with the top 400 genes showing differential expression in GVHD+ versus GVHD- recipients on day 365 (Table S3). Because of overlap between the two gene sets, a total of 711 genes was analyzed. Genes that exhibited little variation across arrays were excluded because they do not contribute useful information for distinguishing among specimens [36]. The basic postulate underlying our analyses was that if the donor profile is largely transferred to the recipient, correlation between a donor on day 0 and its recipient on day 365 (t0i - t3i) would be stronger than (i) correlation of that donor with other donors on day 0 (t0i - t0) and (ii) correlation of that recipient with other recipients on day 365 (t3i - t3). The reverse would be true, and the donor-specific characteristics should be "washed out," if the gene-expression profiles were either unstable or regulated primarily by adaptive (environmental) effects.
###end p 76
###begin p 77
###xml 105 106 105 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 111 112 111 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 183 184 183 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 189 190 189 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 215 216 215 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 221 222 221 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 226 234 226 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040023-g006">Figure 6</xref>
###xml 258 259 258 259 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 267 268 267 268 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 337 345 337 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040023-g006">Figure 6</xref>
We found that the average gene-expression profile correlation among corresponding donor-recipient pairs (t0i - t3i) was consistently higher than the average correlation among donors (t0i - t0) and among recipients (t3i - t3) (Figure 6). This was true for CD4+ and CD8+ T cells, in recipients that were cGVHD+ and those that were cGVHD- (Figure 6). Thus, interindividual differences in expression of GVHD-associated transcripts are remarkably stable over time (365 days). Stability over time increases their potential value as predictive markers. The donor gene-expression profiles are also very robust since they persist following transfer in a different host (the recipient) even in the presence of confounding disease-related factors (cGVHD and its treatment). The stability and "transferability" of the GVHD-linked gene-expression profiles point to a major genetic (as opposed to environmental) influence. Since donors and recipients were siblings it is formally possible that the similar environments (nonhematolymphoid cells) in which T cells resided may have contributed to the transferability of the T cell-expression profiles.
###end p 77
###begin title 78
The Pre-AHCT Donor Gene Expression Profile Correlates with the Recipient Expression Profile Examined One Year Post-AHCT
###end title 78
###begin p 79
###xml 106 114 106 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040023-st003">Table S3</xref>
###xml 396 397 396 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 402 403 402 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 475 476 475 476 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 481 482 481 482 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 570 571 570 571 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 780 781 780 781 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 786 787 786 787 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 836 837 836 837 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 842 843 842 843 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 851 852 851 852 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 857 858 857 858 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 1027 1028 1027 1028 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1049 1050 1049 1050 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 1055 1056 1055 1056 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 1094 1095 1094 1095 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1116 1117 1116 1117 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1131 1132 1131 1132 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1137 1139 1137 1139 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;6</sup>
The Pearson correlation coefficient (rho) over the expression vectors of 711 informative genes (listed in Table S3) was calculated between members of all matching donor-recipient pairs, and all donor-donor and recipient-recipient pairs, and then averaged for each group. Bar graphs show the mean Pearson correlation coefficient between individual donors on day 0 with their recipient on day 365 (t0i - t3i) (red bar), between individual donors and all other donors on day 0 (t0i - t0) (yellow bar), and between individual recipients and all other recipients on day 365 (t3i - t3) (blue bar). Data are from all (40) donor-recipient pairs (A), or from pairs in which the recipient presented cGVHD (B), or not (C). Error bars represent the standard error of the mean. The vector of (t0i - t3i) correlations was compared to the vectors of (t0i - t0) and (t3i - t3) correlations using Student's t-test, to determine whether the differences between these observed sample pair correlation groups are statistically significant. t-Test p-values relative to (t0i - t3i) are labeled as follows: *, 0.01 < p < 0.05; **, 0.001 < p < 0.01; ***, p < 10-6.
###end p 79
###begin title 80
Discussion
###end title 80
###begin p 81
###xml 883 884 880 881 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 892 893 889 890 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1474 1502 1462 1490 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(EP300, FNBP3, FURIN, SMAD3)</italic>
###xml 1536 1549 1521 1534 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(TGFBI, TGIF)</italic>
###xml 1574 1579 1559 1564 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRF1,</italic>
###xml 1612 1619 1594 1601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040023-t002">Table 2</xref>
###xml 1656 1663 1635 1642 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(TGFB1)</italic>
###xml 1682 1689 1661 1668 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(TGFBR2</italic>
###xml 1694 1701 1673 1680 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBR3)</italic>
###xml 2052 2060 2028 2036 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040023-g006">Figure 6</xref>
###xml 2568 2570 2531 2533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b066">66</xref>
###xml 2728 2730 2688 2690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b067">67</xref>
###xml 2731 2733 2691 2693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b068">68</xref>
Several conclusions can be drawn from our work. First, the donor gene-expression profile has a dominant influence on the occurrence of aGVHD and cGVHD in the recipient. Second, extensive studies on cGVHD prediction revealed that the "dangerous donor" trait (occurrence of GVHD in the recipient) is under polygenic control and is determined by competitive and synergistic gene interactions. Third, the risk of cGVHD is shaped by the activity of genes that regulate diverse cell functions in donor T cells, including TGF-beta signaling and cell proliferation. Finally, the donor gene profile persists long-term in the recipient. We wish to emphasize that several convergent pieces of evidence underpin the robustness of conclusions presented herein: (i) in microarray experiments, the donor gene profile defined on day 0 showed exceedingly strong correlation with that of recipient CD4+ and CD8+ T cells harvested on day 365; (ii) for most genes tested by qRT-PCR, differential gene expression between cGVHD+ and cGVHD- donors was confirmed to be robust, on the basis of statistical tests and computational analysis of independent training-test datasets; (iii) from a pathway perspective, differential expression of TGF-beta-related transcripts was entirely consistent with increased TGF-beta signaling in T cells from cGVHD- relative to cGVHD+ donors. Compared with cGVHD+ donors, cGVHD- donors showed higher levels of activating components of the TGF-beta signaling pathway (EP300, FNBP3, FURIN, SMAD3) and of genes induced by TGF-beta (TGFBI, TGIF) but lower expression of PRF1, which is repressed by TGF-beta (Table 2). Notably, transcripts for TGF-beta (TGFB1) and its receptors (TGFBR2 and TGFBR3) were represented on the microarrays and were not differentially expressed in T cells from cGVHD+ relative to cGVHD- donors (unpublished data). Collectively, these data suggest that under basal conditions interindividual variations exist in TGF-beta signaling activity. Moreover, they imply that these interindividual variations are stable over time (Figure 6) and are due, at least in part, to differential expression of intracellular TGF-beta pathway components rather than membrane-associated factors. The latter idea is consistent with recent data on Wnt and TGF-beta signaling. Among thymocyte subsets, differential responsiveness to Wnt signals is not determined by expression of membrane-associated factors, but rather by the balance between activating and inhibiting intracellular components of the Wnt pathway (e.g., beta-catenin, gamma-catenin, and TCF-1) [66]. In addition, two recent studies demonstrated that modulation of SMAD proteins such as SMAD3 was sufficient to regulate the strength of TGF-beta signaling [67,68].
###end p 81
###begin p 82
###xml 119 120 119 120 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 128 129 128 129 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 764 766 758 760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b042">42</xref>
###xml 873 875 864 866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b069">69</xref>
###xml 1143 1144 1131 1132 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1148 1149 1136 1137 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1192 1194 1180 1182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b042">42</xref>
###xml 1195 1197 1183 1185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b070">70</xref>
###xml 1198 1200 1186 1188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b077">77</xref>
###xml 1408 1410 1390 1392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b078">78</xref>
###xml 1557 1559 1536 1538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b079">79</xref>
###xml 1231 1235 <span type="species:ncbi:10090">mice</span>
To the best of our knowledge, our study is the first to present evidence that differential gene expression in donor CD4+ and CD8+ T cells is predictive of the risk of GVHD in the recipient. As mentioned in the Introduction, histoincompatibility is necessary but not sufficient to elicit GVHD. On the basis of our data, we propose that the occurrence of GVHD is determined by another key factor: a dangerous donor (strong alloresponder). Further studies are required to decipher how this complex polygenic trait is regulated. Nevertheless, the concept that TGF-beta signaling in donor cells has a protective role against GVHD is consistent with the well-known pivotal function of TGF-beta in maintaining tolerance and preventing the development of immunopathology [42]. TGF-beta is the cytokine expressed constitutively at highest levels in lymphoid and nonlymphoid organs [69], and its pervasive influence on immune responses results from pleiotropic effects. TGF-beta blocks T cell proliferation, inhibits differentiation of Th1 (T helper class 1) cells and CTLs (cytotoxic T lymphocytes), and promotes expansion as well as maintenance of CD4+CD25+ regulatory T cells that can inhibit GVHD [42,70-77]. Moreover, recent studies in mice have shown that production of TGF-beta by donor T cells early after AHCT attenuates GVHD, and that neutralization of TGF-beta significantly increases the severity of GVHD [78]. Since AHCT is generally used to treat hematologic malignancies, the fact that TGF-beta has a tumor suppressor role in hematologic malignancies [79] might constitute an additional benefit associated with induction of the TGF-beta pathway.
###end p 82
###begin p 83
###xml 75 81 72 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCIRG1</italic>
###xml 89 94 86 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TIRC7</italic>
###xml 207 214 204 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040023-t002">Table 2</xref>
###xml 257 263 254 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCIRG1</italic>
###xml 508 510 501 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b057">57</xref>
###xml 511 513 504 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b080">80</xref>
###xml 624 626 617 619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b081">81</xref>
###xml 627 629 620 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b082">82</xref>
Among cGVHD-predictive genes that are not related to the TGF-beta pathway, TCIRG1 (alias TIRC7) is of particular interest, since it ranked first in terms of statistical significance for prediction of cGVHD (Table 2). GVHD- donors expressed higher levels of TCIRG1 transcripts than GVHD+ donors. This is consistent with the function of TCIRG1, which colocalizes with the T cell receptor and mediates inhibitory signals that lead to up-regulation of CTLA4 and repression of interleukin-2 and interferon-gamma [57,80]. Remarkably, TCIRG1-specific stimulatory antibodies significantly prolonged heart and kidney graft survival [81,82].
###end p 83
###begin p 84
###xml 316 318 316 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b083">83</xref>
###xml 319 321 319 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b085">85</xref>
###xml 563 571 563 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040023-g006">Figure 6</xref>
During the early months post-AHCT, recipient T cells derive to a large extent from proliferation of mature donor T cells present in the graft. However, by one year post-AHCT, recipient T cells derive mainly, if not exclusively, from development of donor-derived hematolymphoid progenitors in the recipient's thymus [83-85]. Thus, on day 365, recipient T cells originate essentially from donor hematopoietic stem cells as opposed to donor post-thymic T cells. The fact that the pre-AHCT donor gene profile correlates with the recipient profile one year post-AHCT (Figure 6) is therefore quite remarkable. These data provide compelling, albeit indirect, evidence that a significant portion of the differential gene profiles between GVHD+ and GVHD- donors is imprinted at the hematopoietic stem cell level. Moreover, stability of the gene-expression profiles in the donor and recipient over a one-year period suggests that the profiles result from inherited genetic traits as opposed to environmental factors. Genetic linkage analyses will be needed to test directly this inference.
###end p 84
###begin p 85
###xml 175 182 175 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040023-t002">Table 2</xref>
###xml 701 709 701 709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040023-g003">Figure 3</xref>
###xml 714 722 714 722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040023-g004">Figure 4</xref>
###xml 911 919 911 919 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040023-g004">Figure 4</xref>
###xml 1091 1093 1091 1093 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b030">30</xref>
###xml 1787 1789 1787 1789 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040023-b086">86</xref>
###xml 1531 1543 <span type="species:ncbi:9606">participants</span>
###xml 1697 1705 <span type="species:ncbi:9606">patients</span>
Can identification of strong versus weak alloresponders be used to select AHCT donors? The predictive value of our best genes was about 80% based on the LDA model separatrix (Table 2). However, predictive models and separatrices can be fine tuned for clinical decision-making to either optimize sensitivity or specificity. An increase in sensitivity usually comes at the expense of a decrease in specificity, and vice versa. Given that the avoidance of GVHD is usually paramount, one would expect that a bias toward the best achievable sensitivity, allowing for the most reliable (or total) elimination of GVHD+ donors (while not eliminating too many donor candidates), would be clinically desirable (Figure 3 and Figure 4). Interestingly, PIA based on a pairwise gene-interaction model suggested that some genes have synergistic or competitive interactions that lead to increased predictive-model performance (Figure 4). This result also suggests that higher-order combinatorial searches beyond two genes could improve significantly the predictive performance of gene-expression profiling [30]. Thus, predictive models limited to a set of ten to 20 genes may achieve even greater than 80% accuracy and the robustness required for dependable AHCT donor selection. However, higher-order predictive variable combinations do require the support of many more samples to prevent overfitting of the model. Cogent assessment of this question will therefore necessitate expression profiling of genes identified herein in larger cohorts of participants. Thus, before gene-expression profiling can be widely used to guide clinical decision-making, it must be validated at other centers, in a wider range of patients. Similar to a recently reported index for post-AHCT assessment of GVHD severity [86], we envision predictive models based on pre-AHCT donor-expression profiling as an "evolving" evidence-based process for determining the risk of GVHD, to be recalibrated over time to account for changes in practice. As a corollary, a gene set that can identify strong alloresponders should also have predictive value for rejection of solid organ grafts. In summary, the results presented here could represent the basis of a breakthrough in transplantation medicine by helping selection of low-risk donors for AHCT, and tailoring the immunosuppressive regimens given to the recipient according to the risk of GVHD (AHCT) or rejection (solid organ).
###end p 85
###begin title 86
Supporting Information
###end title 86
###begin title 87
Genes Overexpressed in GVHD+ Relative to GVHD- Donors
###end title 87
###begin p 88
(22 KB XLS)
###end p 88
###begin p 89
Click here for additional data file.
###end p 89
###begin title 90
Genes Repressed in GVHD+ Relative to GVHD- Donors
###end title 90
###begin p 91
(23 KB XLS)
###end p 91
###begin p 92
Click here for additional data file.
###end p 92
###begin title 93
The Two Gene Sets That Were Used to Evaluate the Correlation between the Donor and Recipient Gene Expression Profiles
###end title 93
###begin p 94
They include the top 400 genes showing differential expression in GVHD+ versus GVHD- donors on day 0, combined with the top 400 genes showing differential expression in GVHD+ vs. GVHD- recipients on day 365.
###end p 94
###begin p 95
(126 KB XLS)
###end p 95
###begin p 96
Click here for additional data file.
###end p 96
###begin title 97
Translation of the Abstract into French by Claude Perreault
###end title 97
###begin p 98
(26 KB DOC)
###end p 98
###begin p 99
Click here for additional data file.
###end p 99
###begin title 100
Accession Numbers
###end title 100
###begin p 101
###xml 268 272 268 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGIF</italic>
###xml 277 282 277 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
###xml 403 411 403 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040023-st001">Table S1</xref>
###xml 416 424 416 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040023-st002">Table S2</xref>
Microarray data in this paper are compliant to the minimum information about a microarray experiment (MIAME) criteria and are deposited at Gene Expression Omnibus (; accession number GSE4624). The National Center for Biotechnology Information () accession numbers for TGIF and TGFBI transcripts are NM_170695 and NM_000358, respectively. Those for all other transcripts used in this study are listed in Table S1 and Table S2.
###end p 101
###begin p 102
###xml 63 68 <span type="species:ncbi:9606">Human</span>
CP and RPS hold Canada Research Chairs in Immunobiology and in Human Immunology, respectively. We are grateful to Abdelkader Yachou for management of the S2K Genome Quebec/Canada program, Claudette Fortin and Helene Grange for judicious comments, and Caroline Cote for technical help.
###end p 102
###begin title 103
Abbreviations
###end title 103
###begin p 104
acute graft-versus-host disease
###end p 104
###begin p 105
allogeneic hematopoietic cell transplantation
###end p 105
###begin p 106
chronic graft-versus-host disease
###end p 106
###begin p 107
competitive predictive interaction analysis
###end p 107
###begin p 108
graft-versus-host disease
###end p 108
###begin p 109
linear discriminant analysis
###end p 109
###begin p 110
major histocompatibility complex
###end p 110
###begin p 111
predictive interaction analysis
###end p 111
###begin p 112
quantitative real-time PCR
###end p 112
###begin p 113
synergistic predictive interaction analysis
###end p 113
###begin p 114
transforming growth factor-beta
###end p 114
###begin title 115
References
###end title 115
###begin article-title 116
Transplantation immunology
###end article-title 116
###begin article-title 117
Minor histocompatibility antigens
###end article-title 117
###begin article-title 118
###xml 99 105 <span type="species:ncbi:10090">murine</span>
Distinct roles for donor- and host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: Requirements depend on target organ
###end article-title 118
###begin article-title 119
The non-MHC transplantation antigens: Neither weak nor minor
###end article-title 119
###begin article-title 120
Minor histocompatibility antigens
###end article-title 120
###begin article-title 121
Evaluation of in vitro cytotoxic T lymphocyte assays as a predictive test for the occurrence of graft vs host disease
###end article-title 121
###begin article-title 122
Increased disparity for minor histocompatibility antigens as a potential cause of increased GVHD risk in marrow transplantation from unrelated donors compared with related donors
###end article-title 122
###begin article-title 123
Graft-versus-host reactions: Clues to the etiopathology of a spectrum of immunological diseases
###end article-title 123
###begin article-title 124
###xml 53 59 <span type="species:ncbi:10090">murine</span>
T-cell interactions in autoimmunity: Insights from a murine model of graft-versus-host disease
###end article-title 124
###begin article-title 125
Target antigens determine graft-versus-host disease phenotype
###end article-title 125
###begin article-title 126
Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation
###end article-title 126
###begin article-title 127
Genetic polymorphisms predicting the outcome of bone marrow transplants
###end article-title 127
###begin article-title 128
###xml 70 74 <span type="species:ncbi:10090">mice</span>
Serum concentrations and allotypes of immunoglobulins in two lines of mice genetically selected for "high" or "low" antibody synthesis
###end article-title 128
###begin article-title 129
###xml 52 56 <span type="species:ncbi:10090">mice</span>
Cytodynamics of the immune response in two lines of mice genetically selected for "high" and "low" antibody synthesis
###end article-title 129
###begin article-title 130
###xml 46 51 <span type="species:ncbi:9940">sheep</span>
###xml 72 77 <span type="species:ncbi:10090">mouse</span>
Polygenic regulation of antibody synthesis to sheep erythrocytes in the mouse: A genetic analysis
###end article-title 130
###begin article-title 131
###xml 76 80 <span type="species:ncbi:10090">mice</span>
Toward genetic dissection of high and low antibody responsiveness in Biozzi mice
###end article-title 131
###begin article-title 132
Recent advances in graft-versus-host disease (GVHD) prevention
###end article-title 132
###begin article-title 133
Understanding the alloresponse: New approaches to graft-versus-host disease prevention
###end article-title 133
###begin article-title 134
Pathogenesis and treatment of graft-versus-host disease after bone marrow transplant
###end article-title 134
###begin article-title 135
A survey of diagnosis, management, and grading of chronic GVHD
###end article-title 135
###begin article-title 136
###xml 118 126 <span type="species:ncbi:9606">patients</span>
Acute graft-versus-host disease prophylaxis with methotrexate and cyclosporine after busulfan and cyclophosphamide in patients with hematologic malignancies
###end article-title 136
###begin article-title 137
###xml 56 61 <span type="species:ncbi:9606">human</span>
Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors
###end article-title 137
###begin article-title 138
1994 Consensus Conference on Acute GVHD Grading
###end article-title 138
###begin article-title 139
Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation
###end article-title 139
###begin article-title 140
Limma: Linear models for microarray data
###end article-title 140
###begin article-title 141
Design and analysis of comparative microarray experiments
###end article-title 141
###begin article-title 142
Linear discriminant functions
###end article-title 142
###begin article-title 143
Transcription-based prediction of response to IFNb using supervised computational methods
###end article-title 143
###begin article-title 144
Design issues for cDNA microarray experiments
###end article-title 144
###begin article-title 145
Genomic approaches to hematologic malignancies
###end article-title 145
###begin article-title 146
The molecular program induced in T cells undergoing homeostatic proliferation
###end article-title 146
###begin article-title 147
Microarray data analysis: From disarray to consolidation and consensus
###end article-title 147
###begin article-title 148
###xml 59 64 <span type="species:ncbi:9606">human</span>
Individuality and variation in gene expression patterns in human blood
###end article-title 148
###begin article-title 149
Optimal gene expression analysis by microarrays
###end article-title 149
###begin article-title 150
The T cell surface-How well do we know it?
###end article-title 150
###begin article-title 151
Lethal GVHD across minor histocompatibility barriers: Nature of the effector cells and role of the H-2 complex
###end article-title 151
###begin article-title 152
Immunodominant minor histocompatibility antigens: The major ones
###end article-title 152
###begin article-title 153
Signatures of the immune response
###end article-title 153
###begin article-title 154
RGD peptides released from big-h3, a TGF-beta-induced cell-adhesive molecule, mediate apoptosis
###end article-title 154
###begin article-title 155
Transforming growth factor-beta regulation of immune responses
###end article-title 155
###begin article-title 156
Evidence that furin is an authentic transforming growth factor-beta1-converting enzyme
###end article-title 156
###begin article-title 157
p300 cooperates with Smad3/4 and Runx3 in TGFbeta1-induced IgA isotype expression
###end article-title 157
###begin article-title 158
###xml 35 40 <span type="species:ncbi:9606">human</span>
Functional proteomics mapping of a human signaling pathway
###end article-title 158
###begin article-title 159
Regulation of TG-interacting factor by transforming growth factor-beta
###end article-title 159
###begin article-title 160
TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance
###end article-title 160
###begin article-title 161
Recent advances in the protein kinase B signaling pathway
###end article-title 161
###begin article-title 162
Homeotic factor ATBF1 induces the cell cycle arrest associated with neuronal differentiation
###end article-title 162
###begin article-title 163
CD24 expression on T cells is required for optimal T cell proliferation in lymphopenic host
###end article-title 163
###begin article-title 164
###xml 20 24 <span type="species:ncbi:10090">mice</span>
Characterization of mice lacking the tetraspanin superfamily member CD151
###end article-title 164
###begin article-title 165
The myc gene family proteins and their role in transformation and differentiation
###end article-title 165
###begin article-title 166
###xml 20 24 <span type="species:ncbi:10090">mice</span>
NFAT5/TonEBP mutant mice define osmotic stress as a critical feature of the lymphoid microenvironment
###end article-title 166
###begin article-title 167
Functional association of Nmi with Stat5 and Stat1 in IL-2- and IFNgamma-mediated signaling
###end article-title 167
###begin article-title 168
Structural characterization of SIL, a gene frequently disrupted in T-cell acute lymphoblastic leukemia
###end article-title 168
###begin article-title 169
Cbl-CIN85-endophilin complex mediates ligand-induced downregulation of EGF receptors
###end article-title 169
###begin article-title 170
TIRC7 deficiency causes in vitro and in vivo augmentation of T and B cell activation and cytokine response
###end article-title 170
###begin article-title 171
A new approach to decoding life: Systems biology
###end article-title 171
###begin article-title 172
Causal protein-signaling networks derived from multiparameter single-cell data
###end article-title 172
###begin article-title 173
Cytotoxic T lymphocytes: All roads lead to death
###end article-title 173
###begin article-title 174
Sil overexpression in lung cancer characterizes tumors with increased mitotic activity
###end article-title 174
###begin article-title 175
Analysis of T-cell repopulation after allogeneic bone marrow transplantation: Significant differences between recipients of T-cell depleted and unmanipulated grafts
###end article-title 175
###begin article-title 176
###xml 62 67 <span type="species:ncbi:9606">human</span>
Polyclonal hematopoiesis with variable telomere shortening in human long-term allogeneic marrow graft recipients
###end article-title 176
###begin article-title 177
Relapse after bone marrow transplantation: Evidence for distinct immunological mechanisms between adult and paediatric populations
###end article-title 177
###begin article-title 178
Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: Recommendations from a workshop at the 2001 Tandem Meetings of the International Bone Marrow Transplant Registry and the American Society of Blood and Marrow Transplantation
###end article-title 178
###begin article-title 179
Wnt signaling in the thymus is regulated by differential expression of intracellular signaling molecules
###end article-title 179
###begin article-title 180
###xml 109 114 <span type="species:ncbi:9606">human</span>
Pro- and antiinflammatory cytokine signaling: reciprocal antagonism regulates interferon-gamma production by human natural killer cells
###end article-title 180
###begin article-title 181
Smad3 reduces susceptibility to hepatocarcinoma by sensitizing hepatocytes to apoptosis through downregulation of Bcl-2
###end article-title 181
###begin article-title 182
T cell zones of lymphoid organs constitutively express Th1 cytokine mRNA: Specific changes during the early phase of an immune response
###end article-title 182
###begin article-title 183
Transforming growth factor-beta controls T helper type 1 cell development through regulation of natural killer cell interferon-gamma
###end article-title 183
###begin article-title 184
###xml 61 62 54 55 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 51 57 <span type="species:ncbi:10090">murine</span>
TGF-beta1 inhibits T-bet induction by IFN-gamma in murine CD4+ T cells through the protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-1
###end article-title 184
###begin article-title 185
###xml 42 43 39 40 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 47 48 44 45 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
IL-10 and TGF-beta induce alloreactive CD4+CD25- T cells to acquire regulatory cell function
###end article-title 185
###begin article-title 186
###xml 60 61 57 58 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 65 66 62 63 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
TGF-beta regulates in vivo expansion of Foxp3-expressing CD4+CD25+ regulatory T cells responsible for protection against diabetes
###end article-title 186
###begin article-title 187
###xml 67 68 64 65 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 72 73 69 70 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells
###end article-title 187
###begin article-title 188
###xml 3 4 3 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 8 9 8 9 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation
###end article-title 188
###begin article-title 189
###xml 3 4 3 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 8 9 8 9 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
CD4+CD25+ immunoregulatory T Cells: New therapeutics for graft-versus-host disease
###end article-title 189
###begin article-title 190
###xml 50 51 50 51 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 55 56 55 56 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
The infusion of ex vivo activated and expanded CD4+CD25+ immune regulatory cells inhibits graft-versus-host disease lethality
###end article-title 190
###begin article-title 191
TGFbeta in allogeneic stem cell transplantation: Friend or foe?
###end article-title 191
###begin article-title 192
Role of transforming growth factor-beta in hematological malignancies
###end article-title 192
###begin article-title 193
TIRC7 pathway as a target for preventing allograft rejection
###end article-title 193
###begin article-title 194
Prevention of acute allograft rejection by antibody targeting of TIRC7, a novel T cell membrane protein
###end article-title 194
###begin article-title 195
###xml 117 121 <span type="species:ncbi:10090">mice</span>
Monoclonal antibody specific for TIRC7 induces donor-specific anergy and prevents rejection of cardiac allografts in mice
###end article-title 195
###begin article-title 196
Factors influencing T-lymphopoiesis after allogeneic hematopoietic cell transplantation
###end article-title 196
###begin article-title 197
Evidence for adequate thymic function but impaired naive T-cell survival following allogeneic hematopoietic stem cell transplantation in the absence of chronic graft-versus-host disease
###end article-title 197
###begin article-title 198
Age-dependent incidence, time course, and consequences of thymic renewal in adults
###end article-title 198
###begin article-title 199
An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens
###end article-title 199
###begin p 200
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Author contributions.</bold>
###xml 72 80 <span type="species:ncbi:9606">patients</span>
Author contributions. CB and CP designed the study. DCR and LB enrolled patients. RS, LDG, DCR, LB, and RPS gave comments at each stage. CB and VR purified T cell subsets and extracted RNA. RS, LDG, and CRC were involved in the conception and design of the mathematical model and statistical analysis of model results. MJC and DJK supervised RNA amplification and microarray hybridization. PW and MJC performed microarray data preprocessing. CB and PC performed and analyzed real-time RT-PCR. CB, RS, LDG, and CP drafted the manuscript. VR, PW, CRC, MJC, DJK, PC, DCR, LB, and RPS reviewed the work and edited the manuscript.
###end p 200
###begin p 201
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests:</bold>
Competing Interests: The University of Montreal has filed a provisional patent application entitled "Assessment and reduction of risk of graft-versus-host disease" that is based on the present work. CB, RS, LDG, and CP are listed as co-inventors on that provisional patent application.
###end p 201
###begin p 202
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding:</bold>
Funding: This work was supported by Genome Quebec, Genome Canada, the Dana Foundation, and the Fonds de la Recherche en Sante du Quebec (Groupe de recherche transdisciplinaire sur l'etude des predicteurs de rejet). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 202

